The first provides guidance on presenting risk and benefit information for prescription drugs and medical devices on Internet/social media platforms with character space limitations such as Twitter and the paid search results links on Google and Yahoo. The second offers guidance on correcting independent third-party misinformation about prescription drugs and medical devices using Internet/social media platforms.

The guidances were designed with patients in mind, according to the FDA.